Skip to main content
. 2020 Dec 31;19(1):83–94. doi: 10.5217/ir.2019.09160

Fig. 1.

Fig. 1.

GEMINI 2 study schematic with number of patients in each treatment arm. During the induction phase, the Asian subgroup included 34 patients randomized to vedolizumab (cohort 1) and 17 to placebo; 24 patients received open-label vedolizumab. During the maintenance phase, in the Asian subgroup, 7 patients were randomized to placebo and 23 patients to the vedolizumab groups.